Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ONCY - ONCOLYTICS BIOTECH INC

Previous close
0.9527
0   0%

Share volume: 171,313
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.25%

PREVIOUS CLOSE
CHG
CHG%
$0.95
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
44%
Profitability 50%
Dept financing 16%
Liquidity 37%
Performance 46%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.13%
1 Month
-8.67%
3 Months
-11.20%
6 Months
-5.98%
1 Year
-58.12%
2 Year
-31.99%
Key data
Stock price
$0.95
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.85 - $2.42
52 WEEK CHANGE
-$0.60
MARKET CAP 
73.842 M
YIELD 
N/A
SHARES OUTSTANDING 
76.999 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
BETA 
1.05
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$130,270
AVERAGE 30 VOLUME 
$220,369
Company detail
CEO: Matthew C. Coffey
Region: US
Website: oncolyticsbiotech.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Oncolytics Biotech Inc. focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Recent news